Ten research investigations

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Does raising HDL and lowering triglycerides by adding prescription-strength niacin reduce coronary events in statin-treated vascular-disease populations?

**Primary study A:** AIM-HIGH Investigators (2011), [PMID 22085343](https://pubmed.ncbi.nlm.nih.gov/22085343/), DOI [10.1056/NEJMoa1107579](https://doi.org/10.1056/NEJMoa1107579). Randomized, double-blind clinical trial, **3,414** adults with established vascular disease and LDL controlled with statin-based therapy. Niacin versus comparator for mean **3 years**, stopped for lack of efficacy.

**AIM-HIGH results:** Primary composite vascular outcome **16.4% niacin vs 16.2% comparator**; HR **1.02**, 95% CI **0.87–1.21**, p=.79 (null). At two years HDL increased, triglycerides decreased, and LDL decreased significantly in niacin group, **without clinical-event improvement**. Neither favorable HDL change nor a numerical endpoint difference can be recast as heart-attack protection.

**Primary study B:** HPS2-THRIVE Collaborative Group (2014), [PMID 25014686](https://pubmed.ncbi.nlm.nih.gov/25014686/), DOI [10.1056/NEJMoa1300955](https://doi.org/10.1056/NEJMoa1300955). Randomized **25,673** participants with atherosclerotic vascular disease already receiving statin-based LDL lowering; **niacin plus laropiprant** vs placebo, median **3.9 years**. Major vascular events **13.2% vs 13.7%**; RR **0.96**, 95% CI **0.90–1.03**, p=.29 (null). Significantly increased serious diabetes-control problems, new diabetes diagnoses, gastrointestinal, musculoskeletal, infection, and bleeding event categories.

**Key safety/identity distinction:** HPS2-THRIVE tested a **combination (niacin + laropiprant)**; its harm magnitude must not automatically be attributed to isolated niacin, food niacin, or a routine multivitamin. AIM-HIGH and HPS2 are **different trials and participant populations** and may be described as convergent null clinical-outcome evidence, without pooling hazards from mismatched formulations.

**Research verdict:** Human RCT, strong negative support against an unqualified claim that raising HDL with high-exposure niacin plus background statins prevents cardiovascular events. **P0 candidate**, but no current-page defect assumed until live content is inspected.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** In generally healthy postmenopausal women, does combined supplementation reduce fractures without harm?

**Primary parent trial:** Jackson et al. (2006), [PMID 16481635](https://pubmed.ncbi.nlm.nih.gov/16481635/), DOI [10.1056/NEJMoa055218](https://doi.org/10.1056/NEJMoa055218). Randomized placebo-controlled WHI trial in **36,282 postmenopausal women**, follow-up approximately **7 years**. Calcium carbonate plus vitamin D vs placebo.

**Parent results:** Hip bone mineral density **1.06% higher** with active supplementation, but ITT hip-fracture HR **0.88**, 95% CI **0.72–1.08** (not significant); total-fracture HR **0.96**, 95% CI **0.91–1.02** (not significant). Urinary calculus incidence **increased** (HR **1.17**, 95% CI **1.02–1.34**).

**Same-cohort secondary paper:** Wallace et al. (2011), [PMID 21525191](https://pubmed.ncbi.nlm.nih.gov/21525191/), DOI [10.3945/ajcn.110.003350](https://doi.org/10.3945/ajcn.110.003350). This is an analysis of **the same WHI randomization**, **not** an independent safety replication: **449** participants reported urinary stones in active group vs **381** in placebo, HR 1.17 (95% CI 1.02–1.34). Outcome was **reported clinician-diagnosed urinary stone**, not laboratory-confirmed composition or proof of individual causation.

**Important constraints:** WHI is combined calcium + vitamin D, **not** a vitamin-D-only test. The 7-year kidney-stone signal should not be extrapolated to food calcium, all supplement forms, men, people with diagnosed deficiency, or a different dose. Adherence-adjusted hip-fracture comparisons differed from ITT and cannot displace prespecified ITT evidence without explanation.

**Research verdict:** **P0** benefit-risk precision and combination firewall. Avoid blanket “no benefit for anyone” and avoid “bone-density increase = proven fracture prevention.”

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Does vitamin D by itself reduce incident fractures in people not selected for deficiency or osteoporosis?

**Primary:** LeBoff et al. (2022), [PMID 35939577](https://pubmed.ncbi.nlm.nih.gov/35939577/), DOI [10.1056/NEJMoa2202106](https://doi.org/10.1056/NEJMoa2202106). Ancillary randomized analysis of parent VITAL trial (two-by-two factorial design); **25,871** participants, median **5.3 years**. Randomized vitamin D3 vs placebo; not enrolled based on low vitamin D, osteopenia, or osteoporosis.

**Prespecified outcomes:** **Total fractures:** 769/12,927 vs 782/12,944; HR **0.98**, 95% CI **0.89–1.08**, p=.70. **Nonvertebral** fracture HR **0.97** (95% CI .87–1.07; p=.50); **hip** fracture HR **1.01** (95% CI .70–1.47; p=.96). No clear modification by measured baseline 25-hydroxyvitamin D in this study, but limited deficiency sampling does not settle efficacy in profound deficiency.

**Contrast and guardrail:** WHI (DE13-02) studied **calcium plus vitamin D in postmenopausal women**; VITAL studied **vitamin D randomized independently** among older men and women. Do not pool or call them same intervention. Neither result rules out clinical treatment of confirmed deficiency or osteoporosis-specific prevention plans.

**Research verdict:** P1 population-specific null. “Vitamin D prevents fractures in everyone” is unsupported by VITAL, whereas deficiency-treatment advice requires a different evidence frame.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Does a standardized Ginkgo extract lower incident all-cause dementia or Alzheimer disease in adults aged 75+?

**Primary:** DeKosky et al. (2008), [PMID 19017911](https://pubmed.ncbi.nlm.nih.gov/19017911/), DOI [10.1001/jama.2008.683](https://doi.org/10.1001/jama.2008.683). Multi-center double-blind placebo-controlled **3,069-person** GEM trial; adults at least 75, some with MCI, median **6.1-year** follow-up.

**Results:** **523** participants developed dementia (277 Ginkgo, 246 placebo); all-cause dementia HR **1.12**, 95% CI **0.94–1.33**, p=.21; Alzheimer disease HR **1.16**, 95% CI **0.97–1.39**, p=.11. Baseline MCI progression to dementia HR **1.13**, 95% CI **0.85–1.50**, p=.39. None statistically significant and **none shows prevention benefit**.

**Null nuance:** Numerical HRs above 1 do **not** establish statistically significant increased dementia risk; do not overread as proven harm. Prevention over years is different from short-term working-memory/attention claims, which require other outcome-specific trials. Studied extract must not generalize to every leaf powder or dose.

**Research verdict:** P1 null. Existing repository article `content/articles/ginkgo-biloba.md` already references PMID **19017911**: reconcile/reuse source instead of adding duplicate.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Can popular omega-3 cardiovascular or anti-inflammatory rationale establish a dry-eye symptom benefit?

**Primary:** Dry Eye Assessment and Management Study Research Group / Asbell et al. (2018), [PMID 29652551](https://pubmed.ncbi.nlm.nih.gov/29652551/), DOI [10.1056/NEJMoa1709691](https://doi.org/10.1056/NEJMoa1709691). Randomized placebo-controlled **535** adults with moderate-to-severe dry-eye disease, twelve months. A high-EPA/DHA **fish-derived** combination was compared with an **olive-oil placebo**.

**Primary result:** Mean Ocular Surface Disease Index change −13.9 active vs −12.5 placebo; imputation-adjusted mean difference **−1.9**, 95% CI **−5.0 to +1.1**, **p=.21** (null). Prespecified ocular signs — conjunctival/corneal staining, tear breakup time and Schirmer's test — also **not significantly different**.

**Limitations:** A null trial of specific fish-derived high-dose preparation in defined dry-eye patients does not rule out all omega-3 benefits for other endpoints (e.g. blood triglycerides), all subgroups, or different interventions. Olive oil was the comparator, not necessarily a pharmacologically inert oil; do not suggest omega-3 made the disease worse.

**Research verdict:** P1 efficacy-indication firewall. No automatic change to cardiovascular omega-3 pages based on an ocular trial.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Does one multi-strain capsule prevent antibiotic-associated diarrhea in older hospitalized patients?

**Primary:** Allen et al. (2013), PLACIDE RCT report [PMID 24309198](https://pubmed.ncbi.nlm.nih.gov/24309198/), DOI [10.3310/hta17570](https://doi.org/10.3310/hta17570). Randomized double-blind placebo controlled **2,981** people age ≥65 admitted to UK hospitals and exposed to antibiotics; **2,941** in allocated-treatment analysis. Four defined Lactobacillus/Bifidobacterium strains in specific study product; not an entire probiotic class comparison.

**Results:** Antibiotic-associated diarrhea (AAD) **159/1,470 (10.8%) probiotic vs 153/1,471 (10.4%) placebo**; RR **1.04**, 95% CI **0.84–1.28**, p=.71 (null). C. difficile diarrhea **12 vs 17**, RR **0.71**, 95% CI **0.34–1.47**, p=.35 (nonsignificant, rare event). No meaningful group difference in reported severity, duration, serious adverse events or cost.

**Boundaries:** AAD and C. difficile-associated diarrhea are distinct endpoints; do not claim C. difficile risk reduction from a numerical but nonsignificant ratio. A specific combination in older inpatients does not refute every strain/species studied in different settings, and lack of excess events does not prove safety in high-risk immunocompromised patients (these were excluded).

**Research verdict:** P1 null/strain-population specificity; this RCT is already described in another long-form institutional report, but all PLACIDE publications are **one clinical trial, not independent replications**.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Does prophylactic or early-treatment use of distinct standardized Echinacea root extracts prevent rhinovirus infection or shorten experimentally induced cold illness?

**Primary:** Turner et al. (2005), [PMID 16049208](https://pubmed.ncbi.nlm.nih.gov/16049208/), DOI [10.1056/NEJMoa044441](https://doi.org/10.1056/NEJMoa044441). Randomized **437 volunteers** across prophylaxis-versus-treatment designs and three chemistry-defined **Echinacea angustifolia root extracts**; analysis of **399** successfully challenged with rhinovirus type 39 in isolated setting.

**Results:** **No statistically significant benefit** for infection rates, cold-symptom severity, nasal-secretions volume, nasal lavage neutrophils/interleukin-8, or viral titer for the tested extracts. Outcomes were **not** proof that every Echinacea species, plant part, or preparation has an identical effect.

**Boundary:** Experimentally inoculated virus and precisely controlled extracts differ from community respiratory infections and proprietary multi-herb blends. Null observed trial is still material: cannot claim these tested extracts “stop cold viruses” based on in-vitro immune-modulation speculation. No recommended amounts.

**Research verdict:** P1 evidence-correction candidate with phytochemistry/species firewall.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Does reduced cramp frequency from baseline constitute superiority over placebo?

**Primary:** Roguin Maor et al. (2017), [PMID 28241153](https://pubmed.ncbi.nlm.nih.gov/28241153/), DOI [10.1001/jamainternmed.2016.9261](https://doi.org/10.1001/jamainternmed.2016.9261). Community randomized, double-blind, placebo-controlled trial: **94 randomized** adults with frequent nocturnal leg cramps, four-week oral magnesium oxide intervention vs placebo.

**Primary outcome:** Cramp reductions **−3.41/week** magnesium vs **−3.03/week** placebo; between-group difference **0.38 cramps/week**, p=.67 (null). No significant group differences in cramp duration/severity, sleep or quality of life. Magnesium exposure did not beat placebo despite within-group changes.

**Boundaries:** Study is about **nonpregnant adults with idiopathic nighttime leg cramps** and **magnesium oxide**. Null does not rule out correcting diagnosed magnesium deficiency or magnesium interventions in pregnancy, and cannot be generalized as “magnesium does nothing medically.” Manufacturer supplied product/support; evaluate potential conflict.

**Research verdict:** P1 before/after versus between-group precision, no dose guidance.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Can iron help fatigue without anemia; does a trial justify universal daily iron for unexplained tiredness?

**Primary:** Vaucher et al. (2012), [PMID 22777991](https://pubmed.ncbi.nlm.nih.gov/22777991/), DOI [10.1503/cmaj.110950](https://doi.org/10.1503/cmaj.110950). Multicenter randomized, observer-blinded trial (**closed-label** — not double-blinded) in **198 menstruating women** aged 18–53 with reported unexplained fatigue, hemoglobin >12 g/dL, and ferritin **below 50 µg/L**, 12 weeks. Studied iron form ferrous sulfate.

**Results:** Fatigue scale decreased **47.7% iron vs 28.8% placebo**, difference **−18.9 percentage points** (95% CI −34.5 to −3.2, p=.02). Blood ferritin and hemoglobin improved. **Quality of life (p=.2), depression (p=.97), and anxiety (p=.5) did not differ significantly** between groups.

**Critical limit:** Findings apply only to the selected menstruating, low-ferritin population; fatigue is not a diagnostic test for iron deficiency. Do not generalize to men, children, normal-ferritin adults, iron-overload disorders, or iron self-treatment. Trial studied quantity is exposure documentation, not advice.

**Research verdict:** **P0** population/diagnostic gate. A source-integrity research record already exists at `ops/enrichment-submissions/sessions/session-c/2026-08-30-iron-fatigue-source-integrity.json` for this PMID; reuse it only if the canonical source mapping is valid.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Does a short-term positive adjunct trial prove an independent antidepressant alternative or safe unsupervised stacking?

**Primary:** Papakostas et al. (2010), [PMID 20595412](https://pubmed.ncbi.nlm.nih.gov/20595412/), DOI [10.1176/appi.ajp.2009.09081198](https://doi.org/10.1176/appi.ajp.2009.09081198). Randomized, double-blind placebo-controlled **73** adult patients with major depressive disorder who were inadequate responders to an existing serotonin reuptake inhibitor (SRI). Participants stayed on stable SRI therapy; six weeks.

**Results:** HAM-D defined **response: 36.1% SAMe adjunct vs 17.6% placebo adjunct**; **remission: 25.8% vs 11.7%**. NNT estimates ~6 for response and ~7 for remission from this small study. Discontinuation proportions due to adverse events did not significantly differ (5.1% vs 8.8%), **which does not establish long-term safety or absence of interactions**.

**Interpretive limits:** Adjunctive strategy in **selected SRI nonresponders** is not SAMe monotherapy, a generic wellness/mood booster, clinical equivalence to antidepressants, or proof that combining any supplement with serotonergic therapy is safe. Short trial underpowered to establish uncommon harms, mania/hypomania risk or long-term disease outcomes. Independent medication/interaction review required before public consumer instructions.

**Research verdict:** **P0** safety-interaction/editorial hold, **P1** replication/efficacy certainty. No advice to alter prescribed therapy.

## Research admission checks, source uniqueness, next actions

- **Ten topic-level dossiers:** distinct from DE10/11/12 subjects. Ingredients can already exist on site: topic novelty **is not** PMID/source novelty. Report **12 distinct PMIDs in this document** across 11 randomized trial cohorts (AIM-HIGH, HPS2-THRIVE, WHI, VITAL, GEM, DREAM, PLACIDE, Turner Echinacea, magnesium cramp, low-ferritin iron, SAMe). **WHI primary and follow-on papers are one trial; do not count 12 independent RCTs.**
- **Existing repo coverage:** Ginkgo PMID 19017911 found in `content/articles/ginkgo-biloba.md`. Iron PMID 22777991 found in prior source-integrity material. GitHub code search did not show remaining IDs in its limited default-branch index; **that does not prove novel canonical source identity**.
- **Strong nulls to retain:** AIM-HIGH and HPS2 clinical outcomes; WHI hip-fracture ITT; VITAL total/nonvertebral/hip fractures; GEM all-cause/AD; DREAM symptoms and objective signs; PLACIDE antibiotic-associated and C. difficile prevention; Echinacea viral challenge infection/severity; magnesium leg cramps between-group; iron depression/anxiety/QoL; SAMe discontinuation difference (not a safety guarantee).
- **Causal hierarchy:** RCT randomization is scoped to its exact product, outcome, population, time and comparator. Within-arm response does not imply placebo-adjusted efficacy. Positive ferritin/bone density/lipid changes are surrogate observations, not automatic proof of patient-important outcomes.
- **High-impact review candidate set:** Niacin statin adjunct harms, calcium+D stones, iron diagnostic gating, SAMe combined-medication messaging. These are **P0 *editorial candidates***, not verified claims that any presently deployed page is wrong.
- **Next stage (not performed by this PR):** Verify present content routes and claim nodes; reconcile PMID/DOI/title aliases against canonical workbook; record explicit nulls and cohort identities; independently review proposed public wording; commit separate governed content/runtimes with green exact-head CI; verify published pages/Google indexing if promoted.
- **No invented ROI:** Merging a research dossier alone is neither new indexed content nor evidence of increased traffic, AI citations, revenue or user health benefit.

**No editorial verdict from V or independent human reviewer is claimed.**